All Updates

All Updates

icon
Filter
Funding
Beacon Therapeutics raises USD 170 million in Series B funding to develop AGTC-501, its lead candidate for XLRP
Cell & Gene Therapy
Jul 3, 2024
This week:
Partnerships
Qualcomm and Google partner to develop AI-driven automotive solutions
Auto Tech
Yesterday
Product updates
Meta AI releases LayerSkip to accelerate inference in LLMs
Generative AI Infrastructure
Yesterday
Funding
Freeform secures funding from NVIDIA's NVentures
Additive Manufacturing
Oct 22, 2024
Product updates
Flexxbotics announces compatibility with LMI Technologies for quality inspection
Smart Factory
Oct 22, 2024
Funding
Oxla raises USD 11 million in seed funding to drive commercialization
Data Infrastructure & Analytics
Oct 22, 2024
Product updates
Cohesity enhances Gaia, its AI assistant, with visual data exploration and expanded data sources
Data Infrastructure & Analytics
Oct 22, 2024
Product updates
Finzly launches FedNow service through BankOS platform in AWS marketplace
FinTech Infrastructure
Oct 22, 2024
Product updates
Runway launches Act-One for AI facial expression motion capture
Generative AI Applications
Oct 22, 2024
Product updates
Ideogram launches Canvas for image manipulation and generation
Generative AI Applications
Oct 22, 2024
Partnerships
UiPath partners with Inflection AI to integrate AI solutions for enterprises
Generative AI Applications
Oct 22, 2024
Cell & Gene Therapy

Cell & Gene Therapy

Jul 3, 2024

Beacon Therapeutics raises USD 170 million in Series B funding to develop AGTC-501, its lead candidate for XLRP

Funding

  • Ophthalmic gene therapy company Beacon Therapeutics has raised USD 170 million in a Series B funding round led by Forbion with participation from Syncona Limited, Oxford Science Enterprises, the University of Oxford, TCGX, and Advent Life Sciences.

  • The new funds are expected to accelerate the clinical development of its lead candidate, AGTC-501, for X-linked retinitis pigmentosa (XLRP). 

  • UK-based Beacon Therapeutics is dedicated to restoring and improving vision for patients suffering from a range of prevalent and rare retinal diseases. The company leverages its proprietary gene therapy technologies to address multiple conditions, including X-linked retinitis pigmentosa (XLRP), dry age-related macular degeneration (AMD), and cone-rod dystrophy (CRD).

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.